- Home
- INBX vs AURA Comparison
INBX vs AURA Comparison
Compare INBX & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- AURA
- Stock Information
- Founded
- INBX 2010
- AURA 2007
- Country
- INBX United States
- AURA United States
- Employees
- INBX N/A
- AURA N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- INBX Health Care
- AURA Health Care
- Exchange
- INBX Nasdaq
- AURA Nasdaq
- Market Cap
- INBX 430.2M
- AURA 396.8M
- IPO Year
- INBX 2020
- AURA 2021
- Fundamental
- Price
- INBX $75.68
- AURA $6.03
- Analyst Decision
- INBX Hold
- AURA Strong Buy
- Analyst Count
- INBX 2
- AURA 5
- Target Price
- INBX N/A
- AURA $21.80
- AVG Volume (30 Days)
- INBX 636.9K
- AURA 305.4K
- Earning Date
- INBX 11-13-2025
- AURA 11-13-2025
- Dividend Yield
- INBX N/A
- AURA N/A
- EPS Growth
- INBX N/A
- AURA N/A
- EPS
- INBX N/A
- AURA N/A
- Revenue
- INBX $1,400,000.00
- AURA N/A
- Revenue This Year
- INBX $563.00
- AURA N/A
- Revenue Next Year
- INBX $230.77
- AURA N/A
- P/E Ratio
- INBX N/A
- AURA N/A
- Revenue Growth
- INBX N/A
- AURA N/A
- 52 Week Low
- INBX $10.81
- AURA $4.35
- 52 Week High
- INBX $77.57
- AURA $11.29
- Technical
- Relative Strength Index (RSI)
- INBX 82.05
- AURA 48.86
- Support Level
- INBX $28.16
- AURA $5.62
- Resistance Level
- INBX $77.57
- AURA $6.60
- Average True Range (ATR)
- INBX 5.16
- AURA 0.37
- MACD
- INBX 4.31
- AURA 0.03
- Stochastic Oscillator
- INBX 96.18
- AURA 44.76
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.